Greenwich LifeSciences (GLSI) to Rejoin Russell 2000 Index

Go back to Greenwich LifeSciences (GLSI) to Rejoin Russell 2000 Index

Greenwich LifeSciences Set to Join Russell 2000 Index Again

June 26, 2024 7:33 AM UTC

STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list of additions updated as of June 21, 2024.

CEO Snehal Patel commented, "The addition of our company to the... More